Ganciclovir: Difference between revisions

Revision as of 01:14, 12 September 2020

Analog of deoxyguanosine, competes with deoxyguanosine to inhibit viral DNA polymerase

Resistance in CMV
- Most often conferred by mutations of UL97 kinase, which is required in order to phosphorylate ganciclovir into its active form
- Can also develop through mutations in the target UL54 DNA polymerase

@@ Line 1: / Line 1: @@
+== Background ==
-* Guanosine nucleoside analogue similar to acyclovir
-* Inhibits all [[human herpesviruses]] by inhibiting DNA polymerase
+*Guanosine nucleoside analogue similar to acyclovir
+*Indications: {{#ask: [[Is treated by::ganciclovir]] | default=none}}
+=== Mechanism of Action ===
+*Analog of deoxyguanosine, competes with deoxyguanosine to inhibit viral DNA polymerase
+=== Mechanisms of Resistance ===
+*Resistance in [[CMV]]
+**Most often conferred by mutations of UL97 kinase, which is required in order to phosphorylate ganciclovir into its active form
+**Can also develop through mutations in the target UL54 DNA polymerase
+=== Spectrum of Activity ===
+* Active against [[HSV-1]], [[HSV-2]], [[VZV]], [[CMV]], [[HHV-6]], and [[HHV-8]]
+=== Pharmacokinetics and Pharmacodynamics ===
+*Oral bioavailability 6-8%
+== Safety ==
 * Major toxicity is cytopenias
-* Resistance in [[CMV]]
-** Most often conferred by mutations of UL97 kinase, which is required in order to phosphorylate ganciclovir into its active form
-** Can also develop through mutations in the target UL54 DNA polymerase
-* Oral bioavailability 6-8%
-* Indications: {{#ask: [[Is treated by::ganciclovir]] | default=none}}
 [[Category:Antivirals]]